Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1CNS 1

Conditions

Leukemia, Myeloid, Acute 9Leukemia, Lymphocytic, Chronic, B-Cell 9Myelodysplastic Syndromes 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Non-Hodgkin 6Hematologic Neoplasms 6Lymphoma, Follicular 5Hodgkin Disease 5Burkitt Lymphoma 5Myeloproliferative Disorders 4Multiple Myeloma 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Myelomonocytic, Chronic 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Lymphoma 3Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 3Waldenstrom Macroglobulinemia 2Primary Myelofibrosis 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Neuroblastoma 2Neoplasms 2Melanoma 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, B-Cell 2Leukemia, Hairy Cell 2Leukemia, Biphenotypic, Acute 2Leukemia 2

Interventions

Specimen Handling 1Nivolumab 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Xeroderma Pigmentosum × Ipilimumab × Other hematologic neoplasm × Clear all
NCT04500548 2026-06-10

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

National Cancer Institute (NCI)

Phase 1 Withdrawn
CNSGastrointestinalLymphoidOther hematologic neoplasm

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Lymphoma, Neuroblastoma, Xeroderma Pigmentosum, Central Nervous System Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡